Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14131624 | 1.00 | BTK (0.42) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL14040699 | 1.00 | BTK (0.42) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL30111928 | 0.92 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL2180252 | 0.92 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL2490017 | 0.92 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL13767380 | 0.92 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL2180249 | 0.92 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL2180246 | 0.92 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL2490021 | 0.92 | BTK (0.43) | BTKGAAEPHX1EPHX2NFKB1 | |
| SCHEMBL23419241 | 0.88 | BTK (0.42) | BTKGAAEPHX1EPHX2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1303281-A4 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | disclosed |
| EP-1401453-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-04-06 | — | — | EP | disclosed |
| US-20040229863-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-20040157828-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-08-12 | — | — | US | disclosed |
| EP-1307204-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1401453-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20040034013-A1 | Administering (3-oxo-azepan-4-ylcarbamoyl)-alkyl)amide derivatives to treat cancer metastasis, diseases caused by tissue destruction by lung macrophase, and by positive selection of CD4\"T\" cells by cortical thymic epithelial cells | SMITHKLINE BEECHAM CORPORATION | 2004-02-19 | — | — | US | disclosed |
| EP-1278502-A2 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002092563-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-21 | — | — | WO | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1158986-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
| EP-1158986-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001089451-A2 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001078734-A1 | METHODS OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-25 | — | — | WO | disclosed |
| WO-2000038687-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034013-A1 | Administering (3-oxo-azepan-4-ylcarbamoyl)-alkyl)amide derivatives to treat cancer metastasis, diseases caused by tissue destruction by lung macrophase, and by positive selection of CD4\"T\" cells by cortical thymic epithelial cells | CTSE, CTSZ, CTSS | BTK 4138/4885GAA 646/4885EPHX1 2376/4885 |
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | BTK 2950/4885GAA 61/4885EPHX1 2770/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | BTK 2900/4885GAA 71/4885EPHX1 2710/4885 |
| US-20040229863-A1 | Protease inhibitors | CTSS, CTSE, CTSF | BTK 1997/4885GAA 110/4885EPHX1 1905/4885 |
| US-20040157828-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | BTK 2900/4885GAA 71/4885EPHX1 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.